Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-08-08
2006-08-08
Pryor, Alton (Department: 1616)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C549S026000, C549S354000, C549S388000, C564S355000, C564S360000, C564S361000, C564S363000, C564S379000
Reexamination Certificate
active
07087765
ABSTRACT:
Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).
REFERENCES:
patent: 3258488 (1966-06-01), Judd et al.
patent: 3372193 (1968-03-01), Moffet et al.
patent: 4018895 (1977-04-01), Molloy et al.
patent: 4070373 (1978-01-01), Winter et al.
patent: 4313896 (1982-02-01), Molloy et al.
patent: 5037846 (1991-08-01), Saccomano et al.
patent: 5145870 (1992-09-01), Jakobsen et al.
patent: 5185369 (1993-02-01), Saccomano et al.
patent: 5310756 (1994-05-01), Jakobsen et al.
patent: 5574173 (1996-11-01), Ting et al.
patent: 723349 (1998-01-01), None
patent: 1 051 281 (1959-02-01), None
patent: 33 285 (1964-12-01), None
patent: 1 793 735 (1973-07-01), None
patent: 17 93 735 (1973-07-01), None
patent: 1793735 (1973-07-01), None
patent: 23 35 943 (1975-01-01), None
patent: 4 239 816 (1994-06-01), None
patent: 0 005 658 (1979-04-01), None
patent: 0 208 523 (1987-01-01), None
patent: 0 399 504 (1990-05-01), None
patent: 0 436 332 (1991-07-01), None
patent: 2 277 589 (1976-02-01), None
patent: 2277589 (1976-02-01), None
patent: 1 169 944 (1967-07-01), None
patent: 1 129 029 (1968-10-01), None
patent: 1 129 210 (1968-10-01), None
patent: 1129029 (1968-10-01), None
patent: 1134715 (1968-11-01), None
patent: 1135926 (1968-12-01), None
patent: 300541 (1974-06-01), None
patent: 92/14709 (1992-09-01), None
patent: 93/04036 (1993-03-01), None
patent: 93/04041 (1993-03-01), None
patent: 93/04373 (1993-03-01), None
patent: 95/15959 (1995-06-01), None
patent: 95/21612 (1995-08-01), None
patent: WO 95/21612 (1995-08-01), None
patent: 96/05818 (1996-02-01), None
patent: 96/40097 (1996-12-01), None
patent: 97/46511 (1997-12-01), None
Banciu et al, Carbonium ion reactions, Revue Roumaine de Chimie, 1975, 20(1), 121-7.
Tsvetkova et al, Synthesis of aminoalkylxanthenes and aminothioxanthenes, Khimo-Farmatsevticheski Zhurnal, 1969, 3 (12), 17-20.
U.S. Appl. No. 08/763,480, filed Dec. 11, 1996, Mueller et al.
Akaike et al., “Spider Toxin Blocks Excitatory Amino Acid Responses in Isolated Hippocampal Pyramidal Neurons,”Neuroscience Letters79:326-330 (1987).
Anis et al., “Structure-Activity Relationships of Philanthotoxin Analogs and Polyamines on N-Methyl-D-Aspartate and Nicotinic Acetylcholine Receptors,”Journal of Pharmacology and Experimental Therapeutics254:764-773 (1990).
Artman et al., “Preferential Inhibitory Effects of Arylamine Spider Toxins on NMDA Receptor-Mediated Increases in Cytosolic Calcium,”Society for Neuroscience Abstracts17(Part 1):394 at abstract No. 163.19 (1991).
Ashe et al., “Argiotoxin-636 Blocks Excitatory Synaptic Transmission in Rat Hippocampal CA1 Pyramidal Neurons,”Brain Research480:234-240 (1989).
Banciu et al., “Carbonium ion reactions. XII. Acetolysis of 5-(2-bromoethyl)-5H-dibenzol [a,d] cycloheptene and nitrous acid deamination of 5-(2-aminoethyl)-5H-dibenzo [a,d] cycloheptene,”Revue Roumaine de Chimie20(1):121-127 (1975).
Banciu et al., Chemical Abstracts, vol. 83 Abstract 146868 (1975).
Beckett and Casy, “Configurational Studies in Synthetic Analgesics,”Journal of the Chemical Societypp. 900-904 (Feb. 1955).
Blagbrough and Usherwood, “Polyamine amide toxins as pharmacological tools and pharmaceutical agents,”Proceedings of the Royal Society of Edinburgh99B(1-2):67-81 (1992).
Blagbrough et al., “Anthropod Toxins as Leads for Novel Insecticides: An Assessment of Polyamine Amides as Glutamate Antagonists,”Toxicon30:303-322 (1992).
Blake et al., “2-Methyl-3,3-Diphenyl-3-Propanolamine (2-MDP) Selectively Antagonises N-Methyl-Aspartate (NMA),”Pharmacology Biochemistry&Behavior24:23-25 (1986).
Blaschke et al., “A Single Amino Acid Determines the Subunit-Specific Spider Toxin Block of -Amino-3-Hydroxy-5-Methylisoxazole-4-Propionate/Kainate Receptor Channels,”Proc. Natl. Acad. Sci. USA90:6528-6532 (1993).
Boehringer et al., Chemical Abstracts, vol. 70 Abstract 37664 (1969).
Boehringer Mannheim, Chemical Abstracts, vol. 86 Abstract 16562 (1977).
Brackley et al., “Selective Antagonism of Native and Cloned Kainate and NMDA Receptors by Polyamine-Containing Toxins,”Journal of Pharmacology and Experimental Therapeutics266:1573-1580 (1993).
Bruce et al., “Structure-Activity Relationships of Analogues of The WASP Toxin Philanthotoxin: Non-Competitive Antagonists of Quisqualate Receptors,”Toxicon28(11):1333-1346 (1990).
Burtsev and Savkov, “Calcium Antagonists (Finoptin and Senzit) in the Treatment of Cerebrovascular Disorders,”Klinicheskaia Meditsina67(9):51-54 (1989) (abstract from MEDLINE).
Buschauer et al., “Synthesis and histamine H2agonistic activity of arpromidine analaogues: replacement of the pheniramine-like moiety by non-heterocyclic groups.”Eur. J. Med. Chem. 27:321-330 (1992).
Camps et al., “A New and Efficient One-Pot Preparation of Alkyl Halides From Alcohols,”Synthesis Communicationspp. 511-512 (May 1987).
Chemical Abstracts5:423 (1959).
Chemical Abstracts54:24555-24556 (1960).
Chemical Abstracts54:424a (1960).
Chemical Abstracts66:4375 (1967).
Chemical Abstracts67:3059 (1967).
Chemical Abstracts69:3322 (1968).
Chemical Abstracts Service, Registry Handbook, Reg. No. 114272-62-7 through 116231-28-8, 1988 Supplement.
Cheng and Prusoff, “Relationship Between the Inhibition Constant (K1) and the Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (/50) of an Enzymatic Reaction,”Biochemical Pharmacology22:3099-3108 (1973).
Choi et al., “Glutamate Neurotoxicity in Cortical Cell Culture,”J. Neuroscience7:357-368 (1987).
Choi et al., “Synthesis and Assay of Hybrid Analogs of Argiotoxin-636 and Philanthotoxin-433: Glutamate Receptor Antagonists,”Tetrahedron49:5777-5790 (1993).
Choi, “Glutamate Neurotoxicity and Diseases of the Nervous System,”Neuron1:623-634 (1988).
Collingridge and Davis, “Ch. 9—NMDA receptors and long-term potentiation in the hippocampus,” inThe NMDA Receptor, edited by Watkins and Collingridge, IRL Press, p. 123-135 (1989).
Cramer et al., “Kainic Acid and 4-Aminopyridine Seizure Models in Mice: Evaluation of Efficacy of Anti-Epileptic Agents and Calcium Antagonists,”Life Sciences54:PL271-PL275 (1994).
Davis et al., “Polyamine Spider Toxins Are Potent Un-competitive Antagonists of Rat Cortex Excitatory Amino Acid Receptors,”European Journal of Pharmacology—Molecular Pharmacology Section227:51-56 (1992).
Deneris et al., “Pharmacological and Functional Diversity of Neuronal Nicotinic Acetylcholine Receptors,”TiPS12:34-40 (1991).
Dickenson, “A Cure for Wind-Up: NMDA Receptor Antagonists as Potential Analgesics,”TiPS11:307-309 (1990).
Dingledine et al., “Excitatory Amino Acid Receptors in Epilepsy,”TiPS11:334-338 (1990).
Donevan and Rogawski, “GYKI 52466, a 2,3-Benzodiazepine, is a Highly Selective, Noncompetitive Antagonist of AMPA/Kainate Receptor Responses,”Neuron10:51-59 (1993).
Donevan et al:, “Arcaine Blocks N-Methyl-D-Aspartate Receptor Responses by an Open Channel Mechanism: Whole-Cell and Single-Channel Recording Studies in Cultured Hippocampal Neurons,”Molecular Pharmacology41:727-735 (1992).
Draguhn et al., “Argiotoxin636inhibits NMDA-activated ion channels expressed inXenopusoocytes,”Neuroscience Letters132:187-190 (1991).
Fingl and Woodbury, “Chapter 1—General Principles,” inThe Pharmacological Basis of Therapeutics5th edition, Goodman and Gilman
Moe Scott T.
Mueller Alan L.
Holland & Hart LLP
NPS Pharmaceuticals Inc.
Pryor Alton
LandOfFree
Compounds active at a novel site on receptor-operated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds active at a novel site on receptor-operated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds active at a novel site on receptor-operated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3659311